+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.

Age: 18Years - 80YearsAll GendersPhase 3
370 locations
E

Actively Recruiting

Researchers are evaluating the antiviral effects of S-337395 compared to a placebo in adults who are not hospitalized but have respiratory syncytial virus RSV infection and are at high risk of progressing to severe disease. This phase 2b study focuses on participants starting treatment within 72 hours of RSV symptom onset to assess safety, tolerability, and efficacy. The trial includes adults with specific risk factors such as advanced age and chronic lung or cardiovascular diseases. Participants are randomly assigned to one of three groups a high dose of S-337395 taken orally twice daily for up to 5 days, a low dose of S-337395 taken with the same schedule, or a matching placebo given twice daily for 5 days. The study uses a double-blind design to compare the effects of these treatments. During the study, participants will undergo nasal swabs to measure changes in RSV viral load at multiple time points days 2, 4, and 6. Researchers will also monitor RSV symptom severity, time to symptom resolution, and the presence of the virus over the first 6 days. Safety is assessed by recording any treatment-emergent adverse events up to 28 days after starting treatment. Blood samples will measure the concentration of S-337395, and participants will be observed throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 2
89 locations
P

Actively Recruiting

Researchers are evaluating whether pemafibrate can help prevent worsening of intracranial arterial stenosis ICAS in people who have symptomatic ICAS and high triglyceride levels after an ischemic stroke or transient ischemic attack TIA. This open-label, randomized, parallel-group trial compares a group receiving pemafibrate with a group not receiving it, while all participants continue standard stroke care including antithrombotic therapy and management of vascular risk factors. The study is sponsored by Tokyo Womens Medical University. Participants assigned to the pemafibrate group will take the drug for 12 months, with possible dose adjustments based on triglyceride levels and kidney function. Both groups will receive standard medical therapy. Brain CT angiography CTA will be performed at the start and after 12 months. Additional assessments include brain MRIMRA and vascular tests such as ankle brachial index, cardio ankle vascular index, and pulse wave velocity, conducted according to the study schedule. During the study, participants will have blood tests and clinical assessments at baseline and follow-up visits. Researchers will monitor vascular events, functional outcomes, and adverse events over 12 months. The main outcome measured is progression of intracranial arterial stenosis on CTA at 12 months. Secondary outcomes include changes in stenosis severity, cardiovascular events, mortality, daily living activities, brain imaging markers, vascular indices, blood biomarkers, and safety measures throughout the treatment period.

Age: 18Years +All GendersPhase Not Applicable
42 locations